1. Fagerström K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 2002;62(Suppl 2):1-9.
2. Shiffman S, Mason KM, Henningfield JE. Tobacco dependence treatments: review and prospectus. Annu Rev Public Health 1998;19:335-358. PMID:
9611623.
3. Conklin CA, Tiffany ST. Applying extinction research and theory to cue-exposure addiction treatments. Addiction 2002;97:155-167. PMID:
11860387.
4. Saladin ME, Brady KT, Graap K, Rothbaum BO. A preliminary report on the use of virtual reality technology to elicit craving and cue reactivity in cocaine dependent individuals. Addict Behav 2006;31:1881-1894. PMID:
16516397.
5. Niaura R, Abrams DB, Pedraza M, Monti PM, Rohsenow DJ. Smokers' reactions to interpersonal interaction and presentation of smoking cues. Addict Behav 1992;17:557-566. PMID:
1488936.
6. Droungas A, Ehrman RN, Childress AR, O'Brien CP. Effect of smoking cues and cigarette availability on craving and smoking behavior. Addict Behav 1995;20:657-673. PMID:
8712062.
7. Niaura R, Abrams D, Demuth B, Pinto R, Monti P. Responses to smoking-related stimuli and early relapse to smoking. Addict Behav 1989;14:419-428. PMID:
2782124.
8. Jerome LW, Jordan PJ, Rodericks R, Fedenczuk L. Psychophysiological arousal and craving in smokers, deprived smokers, former smokers, and non-smokers. Stud Health Technol Inform 2009;144:179-183. PMID:
19592759.
10. Miranda R Jr, Rohsenow DJ, Monti PM, Tidey J, Ray L. Effects of repeated days of smoking cue exposure on urge to smoke and physiological reactivity. Addict Behav 2008;33:347-353. PMID:
17913381.
11. Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 1997;5:137-142. PMID:
9234050.
12. Marlatt GA. Cue exposure and relapse prevention in the treatment of addictive behaviors. Addict Behav 1990;15:395-399. PMID:
2248112.
13. Rohsenow DJ, Niaura RS, Childress AR, Abrams DB, Monti PM. Cue reactivity in addictive behaviors: theoretical and treatment implications. Int J Addict 1990-1991;25:957-993. PMID:
2131326.
14. Lee J, Lim Y, Graham SJ, Kim G, Wiederhold BK, Wiederhold MD, et al. Nicotine craving and cue exposure therapy by using virtual environments. Cyberpsychol Behav 2004;7:705-713. PMID:
15687806.
15. McClernon FJ, Hiott FB, Liu J, Salley AN, Behm FM, Rose JE. Selectively reduced responses to smoking cues in amygdala following extinction-based smoking cessation: results of a preliminary functional magnetic resonance imaging study. Addict Biol 2007;12:503-512. PMID:
17573781.
16. Moon J, Lee JH. Cue exposure treatment in a virtual environment to reduce nicotine craving: a functional MRI study. Cyberpsychol Behav 2009;12:43-45. PMID:
19025463.
17. Emmelkamp PM, Krijn M, Hulsbosch AM, de Vries S, Schuemie MJ, van der Mast CA. Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobia. Behav Res Ther 2002;40:509-516. PMID:
12038644.
18. da Costa RT, Sardinha A, Nardi AE. Virtual reality exposure in the treatment of fear of flying. Aviat Space Environ Med 2008;79:899-903. PMID:
18785359.
19. Rothbaum BO, Hodges LF, Ready D, Graap K, Alarcon RD. Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. J Clin Psychiatry 2001;62:617-622. PMID:
11561934.
20. Bordnick PS, Traylor A, Copp HL, Graap KM, Carter B, Ferrer M, et al. Assessing reactivity to virtual reality alcohol based cues. Addict Behav 2008;33:743-756. PMID:
18282663.
21. Bordnick PS, Copp HL, Traylor A, Graap KM, Carter BL, Walton A, et al. Reactivity to cannabis cues in virtual reality environments. J Psychoactive Drugs 2009;41:105-112. PMID:
19705672.
22. Bordnick PS, Graap KM, Copp HL, Brooks J, Ferrer M. Virtual reality cue reactivity assessment in cigarette smokers. Cyberpsychol Behav 2005;8:487-492. PMID:
16232041.
23. Maltby N, Kirsch I, Mayers M, Allen GJ. Virtual reality exposure therapy for the treatment of fear of flying: a controlled investigation. J Consult Clin Psychol 2002;70:1112-1118. PMID:
12362961.
24. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-1127. PMID:
1932883.
25. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorder. 1996,New York: New York State Psychiatric Institute.
26. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict 1991;86:1467-1476. PMID:
1777741.
28. Balfour DJ, Wright AE, Benwell ME, Birrell CE. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 2000;113:73-83. PMID:
10942034.
29. Donny EC, Caggiula AR, Rowell PP, Gharib MA, Maldovan V, Booth S, et al. Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology (Berl) 2000;151:392-405. PMID:
11026746.
30. Wilhelm FH, Pfaltz MC, Gross JJ, Mauss IB, Kim SI, Wiederhold BK. Mechanisms of virtual reality exposure therapy: the role of the behavioral activation and behavioral inhibition systems. Appl Psychophysiol Biofeedback 2005;30:271-284. PMID:
16167191.
31. de Carvalho MR, Freire RC, Nardi AE. Virtual reality as a mechanism for exposure therapy. World J Biol Psychiatry 2010;11:220-230. PMID:
20218785.
32. Kiryu T, So RH. Sensation of presence and cybersickness in applications of virtual reality for advanced rehabilitation. J Neuroeng Rehabil 2007;4:34PMID:
17894857.
33. Viaud-Delmon I, Warusfel O, Seguelas A, Rio E, Jouvent R. High sensitivity to multisensory conflicts in agoraphobia exhibited by virtual reality. Eur Psychiatry 2006;21:501-508. PMID:
17055951.
34. Matthews KA, Davis MC, Stoney CM, Owens JF, Caggiula AR. Does the gender relevance of the stressor influence sex differences in psychophysiological responses? Health Psychol 1991;10:112-120. PMID:
2055209.
35. Swan GE, Ward MM, Jack LM, Javitz HS. Cardiovascular reactivity as a predictor of relapse in male and female smokers. Health Psychol 1993;12:451-458. PMID:
8293728.